Skip to main content

Advertisement

SpringerLink
Log in

Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society

  • Guidelines, Position Statements, Consensus Statements
  • Published:
Hormones Aims and scope Submit manuscript

Abstract

The Bone Section of the Hellenic Endocrine Society has issued the recommendations herein presented with the aim of providing guidance on optimal management of patients with parathyroid disorders in everyday clinical practice within the Greek health care setting. Although the methodology followed to formulate these recommendations was not strictly based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) principles, they were drawn up after an extensive review of the literature and of the currently available guidelines for the management of parathyroid disorders worldwide. Specifically for primary hyperparathyroidism (PHPT), the 2011 guidelines of the Greek National Organization of Medicines were updated accordingly. In particular, definitions, etiologies, and recommended and optional laboratory and imaging examinations are provided both for PHPT and chronic hypoparathyroidism (HypoPT). Finally, treatment algorithms are provided for the management of both PHPT and HypoPT. Specifically for HypoPT, the treatment algorithm describes the recommended steps that should be followed to achieve optimal management of chronic hypocalcemia and the complications of HypoPT through the conventional treatment available in Greece and the use of recombinant human PTH(1-84).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569. https://doi.org/10.1210/jc.2014-1413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3570–3579. https://doi.org/10.1210/jc.2014-1414

    Article  CAS  PubMed  Google Scholar 

  3. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28(1):1–19. https://doi.org/10.1007/s00198-016-3716-2

    Article  CAS  PubMed  Google Scholar 

  4. Bilezikian JP (2018) Primary hyperparathyroidism. J Clin Endocrinol Metab 103(11):3993–4004. https://doi.org/10.1210/jc.2018-01225

    Article  PubMed  PubMed Central  Google Scholar 

  5. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Liu JM, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP (2014) Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3580–3594. https://doi.org/10.1210/jc.2014-1415

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Udelsman R, Akerstrom G, Biagini C, Duh QY, Miccoli P, Niederle B, Tonelli F (2014) The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3595–3606. https://doi.org/10.1210/jc.2014-2000

    Article  CAS  PubMed  Google Scholar 

  7. Anastasilakis DA, Makras P, Polyzos SA, Anastasilakis AD, Part of the CET (2019) Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. Hormones (Athens) 18(1):65–70. https://doi.org/10.1007/s42000-018-0069-6

    Article  Google Scholar 

  8. Cusano NE, Cipriani C, Bilezikian JP (2018) Management of normocalcemic primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab 32(6):837–845. https://doi.org/10.1016/j.beem.2018.09.009

    Article  PubMed  Google Scholar 

  9. Makras P, Kaltsas GA, Athanasoulis T, Papadogias D, Zografos GN, Kontogeorgos G, Borboli N, Piaditis G (2005) Treatment with oral biphosphonates can increase the sensitivity of sestamibi radionuclide imaging in patients with primary hyperparathyroidism. Int J Clin Pharmacol Res 25(1):19–28

    CAS  PubMed  Google Scholar 

  10. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93(9):3462–3470. https://doi.org/10.1210/jc.2007-1215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Makras P, Anastasilakis AD (2018) Bone disease in primary hyperparathyroidism. Metabolism 80:57–65. https://doi.org/10.1016/j.metabol.2017.10.003

    Article  CAS  PubMed  Google Scholar 

  12. Makras P, Anastasilakis AD, Antypas G, Chronopoulos E, Kaskani EG, Matsouka A, Patrikos DK, Stathopoulos KD, Tournis S, Trovas G, Kosmidis C (2019) The 2018 guidelines for the diagnosis and treatment of osteoporosis in Greece. Arch Osteoporos 14(1):39. https://doi.org/10.1007/s11657-019-0584-3

    Article  PubMed  Google Scholar 

  13. Locker FG, Silverberg SJ, Bilezikian JP (1997) Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 102(6):543–550. https://doi.org/10.1016/s0002-9343(97)00053-3

    Article  CAS  PubMed  Google Scholar 

  14. Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM, European Society of E (2015) European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173(2):G1–G20. https://doi.org/10.1530/EJE-15-0628

  15. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT Jr (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101(6):2273–2283. https://doi.org/10.1210/jc.2015-3907

    Article  CAS  PubMed  Google Scholar 

  16. Rodriguez-Ortiz ME, Canalejo A, Herencia C, Martinez-Moreno JM, Peralta-Ramirez A, Perez-Martinez P, Navarro-Gonzalez JF, Rodriguez M, Peter M, Gundlach K, Steppan S, Passlick-Deetjen J, Munoz-Castaneda JR, Almaden Y (2014) Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant 29(2):282–289. https://doi.org/10.1093/ndt/gft400

    Article  CAS  PubMed  Google Scholar 

  17. Karp HJ, Ketola ME, Lamberg-Allardt CJ (2009) Acute effects of calcium carbonate, calcium citrate and potassium citrate on markers of calcium and bone metabolism in young women. Br J Nutr 102(9):1341–1347. https://doi.org/10.1017/S0007114509990195

    Article  CAS  PubMed  Google Scholar 

  18. John DR, Suthar PP (2016) Radiological features of long-standing hypoparathyroidism. Pol J Radiol 81:42–45. doi:https://doi.org/10.12659/PJR.896104

  19. Marcucci G, Cianferotti L, Brandi ML (2018) Clinical presentation and management of hypoparathyroidism. Best Pract Res Clin Endocrinol Metab 32(6):927–939. https://doi.org/10.1016/j.beem.2018.09.007

    Article  CAS  PubMed  Google Scholar 

  20. Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, Mitchell DM, Vokes TJ, Winer KK, Shoback DM (2017) Hypoparathyroidism. Nat Rev Dis Primers 3:17080. https://doi.org/10.1038/nrdp.2017.80

    Article  PubMed  Google Scholar 

  21. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28(11):2277–2285. https://doi.org/10.1002/jbmr.1979

    Article  PubMed  Google Scholar 

  22. Chan FK, Tiu SC, Choi KL, Choi CH, Kong AP, Shek CC (2003) Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 88(7):3155–3159. https://doi.org/10.1210/jc.2002-021388

    Article  CAS  PubMed  Google Scholar 

  23. Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, Silverberg SJ, Bilezikian JP (2008) Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res 23(12):2018–2024. https://doi.org/10.1359/jbmr.080803

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Mendonca ML, Pereira FA, Nogueira-Barbosa MH, Monsignore LM, Teixeira SR, Watanabe PC, Maciel LM, de Paula FJ (2013) Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord 13:1. https://doi.org/10.1186/1472-6823-13-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30(9):1738–1744. https://doi.org/10.1002/jbmr.2501

    Article  CAS  PubMed  Google Scholar 

  26. Formenti AM, Tecilazich F, Giubbini R, Giustina A (2019) Risk of vertebral fractures in hypoparathyroidism. Rev Endocr Metab Disord 20(3):295–302. https://doi.org/10.1007/s11154-019-09507-x

    Article  CAS  PubMed  Google Scholar 

  27. Khan AA, Koch C, Van Uum SHM, Baillargeon JP, Bollerslev J, Brandi ML, Marcocci C, Rejnmark L, Rizzoli R, Shrayyef MZ, Thakker RV, Yildiz BO, Clarke B (2018) Standards of care for hypoparathyroidism in adults. Eur J Endocrinol. https://doi.org/10.1530/EJE-18-0609

  28. Orloff LA, Wiseman SM, Bernet VJ, Fahey TJ 3rd, Shaha AR, Shindo ML, Snyder SK, Stack BC Jr, Sunwoo JB, Wang MB (2018) American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid 28(7):830–841. https://doi.org/10.1089/thy.2017.0309

    Article  PubMed  Google Scholar 

  29. Gafni RI, Collins MT (2019) Hypoparathyroidism. N Engl J Med 380(18):1738–1747. https://doi.org/10.1056/NEJMcp1800213

    Article  PubMed  Google Scholar 

  30. Straub DA (2007) Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 22(3):286–296. https://doi.org/10.1177/0115426507022003286

    Article  PubMed  Google Scholar 

  31. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D, Women's Health Initiative I (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354(7):669–683. https://doi.org/10.1056/NEJMoa055218

    Article  CAS  PubMed  Google Scholar 

  32. Khan AA, Clarke B, Rejnmark L, Brandi ML (2019) Management of endocrine disease: hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. Eur J Endocrinol 180(2):R37–R44. https://doi.org/10.1530/EJE-18-0541

    Article  CAS  PubMed  Google Scholar 

  33. Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97(12):4507–4514. https://doi.org/10.1210/jc.2012-1808

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Maria P. Yavropoulou and Evanthia Kassi contributed equally to this work.

Authors and Affiliations

  1. Department of Endocrinology and Diabetes and Department of Medical Research, 251 Hellenic Air Force General Hospital, Athens, Greece

    Polyzois Makras

  2. Centre of Expertise in Rare Endocrine Diseases, C.E.R.E.D – Disorders of Calcium and Phosphate Metabolism, Endocrinology Unit, 1st Department of Propaedeutic Internal Medicine, LAIKO General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece

    Maria P. Yavropoulou & Evanthia Kassi

  3. Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece

    Athanasios D. Anastasilakis

  4. Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece

    Andromachi Vryonidou

  5. Laboratory for Research of the Musculoskeletal System “Th. Garofalidis”, Medical School, National and Kapodistrian University of Athens, KAT Hospital, Athens, Greece

    Symeon Tournis

Authors
  1. Polyzois Makras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria P. Yavropoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evanthia Kassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Athanasios D. Anastasilakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andromachi Vryonidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Symeon Tournis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Polyzois Makras.

Ethics declarations

Conflict of interest

PM has received lecture fees and research grants from Amgen and has received lecture and/or advisory board fees from Glaxo, Lilly, UCB, Pfizer, Leo, Genesis, ELPEN, VIANEX, and Rafarm; MPY has received lecture fees from Galenica, Shire, and Eli Lilly; EK has received lecture fees from ELPEN, ITF Hellas, and Bausch Health; ADA has received lecture fees from Amgen, Eli Lilly, ELPEN, ITF Hellas, and VIANEX; AV has received lecture fees from Takeda; ST has received lecture and/or advisory board fees from Amgen, Lilly, Vianex, ITF Hellas, Merck Biopharma Greece, Galenica, and Shire.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Makras, P., Yavropoulou, M.P., Kassi, E. et al. Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society. Hormones 19, 581–591 (2020). https://doi.org/10.1007/s42000-020-00195-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42000-020-00195-w

Keywords

Search

Navigation